4-(4-三氟甲氧基苯基)咪唑 | 684221-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(4-三氟甲氧基苯基)咪唑
• 英文名称: 4-(4-trifluoromethoxyphenyl)imidazole
• 英文别名: 4-(4-Trifluoromethoxyphenyl)-1h-imidazole；5-[4-(trifluoromethoxy)phenyl]-1H-imidazole
• CAS: 684221-40-7
• 化学式: C₁₀H₇F₃N₂O
• 分子量: 228.174
• InChiKey: UMCRGEQTUJYEEC-UHFFFAOYSA-N

物化性质

• 密度：
  1.369

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  37.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(4-三氟甲氧基苯基)咪唑 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2S)-N-(3-ethoxypropyl)-4-methyl-2-(6-methyl-2-(4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-1-yl)pyrimidin-4-ylamino)pentanamide
  参考文献：
  名称：

  Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists

  摘要：

  An imidazolylpyrimidine was identified in a CXCR2 chemokine receptor antagonist screen and was optimized for potency, in vitro metabolic stability, and oral bioavailability. It was found that subtle structural modification within the series affected the oral bioavailability. Potent and orally available CXCR2 antagonists are herein reported. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.028
• 作为产物：
  描述：

  2-溴-1-4-(三氟甲氧基)苯基乙酮 、 formamide 生成 4-(4-三氟甲氧基苯基)咪唑
  参考文献：
  名称：

  Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists

  摘要：

  An imidazolylpyrimidine was identified in a CXCR2 chemokine receptor antagonist screen and was optimized for potency, in vitro metabolic stability, and oral bioavailability. It was found that subtle structural modification within the series affected the oral bioavailability. Potent and orally available CXCR2 antagonists are herein reported. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.02.028

文献信息

• Pyrimidine derivatives as IL-8 receptor antagonists
  申请人：——

  公开号：US20040087601A1

  公开（公告）日：2004-05-06

  Compounds containing the pyrimidine nucleus and their use to treat diseases and conditions related to inappropriate Interleukin-8 receptor activity are disclosed. The compounds are of the formula I 1 In these compounds, Q is preferably unsubstituted and substituted heterocyclyl; U is usually hydrogen or fluorine; and V is preferably hydrogen, halogen, alkyl, —O—alkyl or —S-alkyl. A representative example is: 2

  含有嘧啶核的化合物及其用于治疗与不适当的白细胞介素-8受体活性相关的疾病和症状的用途已被披露。这些化合物的结构式为I 1 在这些化合物中，Q最好是未取代或取代的杂环烷基；U通常是氢或氟；V最好是氢、卤素、烷基、—O—烷基或—S-烷基。一个代表性的例子是： 2
• [EN] NOVEL ERYTHROMYCIN DERIVATIVES, METHOD FOR THEIR PREPARATION AND THEIR USE AS DRUGS<br/>[FR] NOUVEAUX DERIVES DE L'ERYTHROMYCINE, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION COMME MEDICAMENTS
  申请人：ROUSSEL UCLAF

  公开号：WO1995029929A1

  公开（公告）日：1995-11-09

  (EN) Compounds of formula (I) in which R is a -(CH2)nAr radical, n is 3, 4 or 5, Ar is an optionally substituted heterocyclic radical and Z is a hydrogen atom or an acid residue. The compounds of formula (I) have useful antibiotic properties.(FR) L'invention a pour objet les composés de formule (I) dans lesquels: R représente un radical -(CH2)nAr, n représentant le nombre 3, 4 ou 5, Ar représentant un radical hétérocyclique, éventuellement substitué, Z représentant un atome d'hydrogène ou le reste d'un acide. Les composés de formule (I) présentent d'intéressantes propriétés antibiotiques.

  (中文翻译) 公式(I)中的化合物，其中R为-(CH2)nAr基团，n为3、4或5，Ar为可选取代的杂环基团，Z为氢原子或酸残基。公式(I)的化合物具有有用的抗生素性质。
• FACTOR XIA INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2978425B1

  公开（公告）日：2017-09-27
• Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists
  作者：Koc-Kan Ho、Douglas S. Auld、Adolph C. Bohnstedt、Paolo Conti、Wim Dokter、Shawn Erickson、Daming Feng、Jim Inglese、Celia Kingsbury、Steven G. Kultgen、Rong-Qiang Liu、Christopher M. Masterson、Michael Ohlmeyer、Yajing Rong、Martijn Rooseboom、Andrew Roughton、Philippe Samama、Martin-Jan Smit、Ellen Son、Jaap van der Louw、Gerard Vogel、Maria Webb、Jac Wijkmans、Ming You

  DOI：10.1016/j.bmcl.2006.02.028

  日期：2006.5

  An imidazolylpyrimidine was identified in a CXCR2 chemokine receptor antagonist screen and was optimized for potency, in vitro metabolic stability, and oral bioavailability. It was found that subtle structural modification within the series affected the oral bioavailability. Potent and orally available CXCR2 antagonists are herein reported. (C) 2006 Elsevier Ltd. All rights reserved.